Neopharm News (NASDAQ:NEOL)
| Latest Neopharm News Headlines | | Date | Time | Source | | | 05/29/2007 | 1:00AM | PRNUS | IDM Pharma Names Timothy P. Walbert as President and CEO
IRVINE, Calif., May 29 /PRNewswire-FirstCall/ -- IDM Pharma (NASDAQ:IDMI) today announced that Timothy P. Walbert, 40, has joined the Company as President and Chief Executive Officer, effective immediately. Mr. Walbert replaces Jean-Loup Romet-Lemonne, M.D., who founded the company and is leaving to pursue other opportunities... More...>> |
| 04/17/2007 | 7:30AM | PRNUS | DATATRAK Appoints New Board Member
CLEVELAND, April 17 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (NASDAQ:DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today reported that it has appointed a new member to its Board of Directors and has expanded the size of the Board to seven.
Mr... More...>> |
| 04/17/2006 | 9:00AM | PRNUS | Bally Appoints Finance Veteran Ron Eidell to Replace CFO; Strategic Process, 2005 Audit and 10-K Filing Remain on Track
CHICAGO, April 17 /PRNewswire-FirstCall/ -- Bally Total Fitness Holding Corporation (NYSE:BFT) today announced Ronald G. Eidell has joined Bally as chief financial officer, assuming responsibility for all finance and accounting functions. Eidell replaces former Chief Financial Officer Carl J. Landeck, who is no longer... More...>> |
| 09/27/2004 | 12:14PM | PRNUS | Shareholder and Director Kapoor Files Definitive Consent Statement
Shareholder and Director Kapoor Files Definitive Consent
Statement
LAKE FOREST, Ill., Sept. 27 /PRNewswire-FirstCall/ -- John N. Kapoor, Ph.D., a
director of NeoPharm, Inc. (NASDAQ:NEOL) and, together with his wife, the
beneficial holder of approximately 21.7% of its outstanding common stock, today
announced that he... More...>> |
| 09/02/2004 | 12:46PM | PRNUS | Shareholder and Director Kapoor Seeks Change in NeoPharm Board
Shareholder and Director Kapoor Seeks Change in NeoPharm Board
LAKE FOREST, Ill., Sept. 2 /PRNewswire-FirstCall/ -- John N. Kapoor, Ph.D., a
director of NeoPharm, Inc. (NASDAQ:NEOL) and, together with his wife, the
beneficial holder of approximately 21.7% of its outstanding common stock, today
announced that he had... More...>> |
| 11/21/2003 | 7:00AM | PRNUS | NeoPharm Signs First Worldwide NeoPhectin(TM) Distribution and Marketing Agreement With Avanti
NeoPharm Signs First Worldwide NeoPhectin(TM) Distribution and Marketing
Agreement With Avanti
NeoPhectin(TM) Will Be Available From Avanti Polar Lipids, Inc. Beginning In
January 2004
LAKE FOREST, Ill., Nov. 21 /PRNewswire-FirstCall/ -- NeoPharm, Inc. announced
today that it has entered into the first distribution... More...>> |
| 11/20/2003 | 7:00AM | PRNUS | NeoPharm and Collaborators Present Preliminary Phase I LE-SN38 And NeoLipid(TM) Data
NeoPharm and Collaborators Present Preliminary Phase I LE-SN38 And NeoLipid(TM)
Data
Presentations Made at AACR-NCI-EORTC Conference and Chemotherapy Foundation
Symposium
LAKE FOREST, Ill., Nov. 20 /PRNewswire-FirstCall/ -- NeoPharm, Inc. announced
today the first preliminary Phase I clinical trial data for LE-SN38... More...>> |
| 11/17/2003 | 7:00AM | PRNUS | NeoPharm and Collaborators Present IL13-PE38QQR Clinical Data in Brain Cancer
NeoPharm and Collaborators Present IL13-PE38QQR Clinical Data in Brain Cancer
Additional and New Preliminary Data Unveiled at SNO 8th Annual Meeting Provide
Consistent Support for Further Development of This Novel Approach in Advance Of
Phase III Clinical Trial
LAKE FOREST, Ill., Nov. 17 /PRNewswire-FirstCall/ -- NeoPharm... More...>> |
| 11/14/2003 | 7:00AM | PRNUS | NeoPharm Announces Third Quarter 2003 Financial Results
NeoPharm Announces Third Quarter 2003 Financial Results
LAKE FOREST, Ill., Nov. 14 /PRNewswire-FirstCall/ -- NeoPharm, Inc. today
announced financial results for the third quarter of 2003. The Company reported
a net loss of $12,219,597 or $0.65 per share, basic and diluted, for the third
quarter 2003 versus a net... More...>> |
| 11/13/2003 | 7:00AM | PRNUS | NeoPharm to Launch New Transfection Agent Using Novel Cationic Cardiolipin
NeoPharm to Launch New Transfection Agent Using Novel Cationic Cardiolipin
NeoPhectin(TM) Commercial Availability Planned for January 2004
LAKE FOREST, Ill., Nov. 13 /PRNewswire-FirstCall/ -- NeoPharm, Inc. announced
today the development of NeoPhectin(TM), a novel in vitro transfection reagent
that is an outgrowth... More...>> |
| 11/06/2003 | 11:04AM | PRNUS | NeoPharm to Present New Clinical Data at Upcoming Scientific Meetings
NeoPharm to Present New Clinical Data at Upcoming Scientific Meetings
Presentations in November Will Feature Preliminary Phase I/II Data For
IL13-PE38QQR and LE-SN38
LAKE FOREST, Ill., Nov. 6 /PRNewswire-FirstCall/ -- NeoPharm, Inc. announced
today that additional Phase I/II clinical trial data on several of the Company's
products... More...>> |
| 11/06/2003 | 7:00AM | PRNUS | NeoPharm Sets Conference Call and Webcast for Third Quarter Results
NeoPharm Sets Conference Call and Webcast for Third Quarter Results
LAKE FOREST, Ill., Nov. 6 /PRNewswire-FirstCall/ -- NeoPharm, Inc. announced
today that its regular quarterly update and conference call to discuss results
for the third quarter ended September 30, 2003 will be held on Friday, November
14, 2003 at... More...>> |
| 10/31/2003 | 10:22AM | PRNUS | NeoPharm Sets Conference Call and Webcast for Third Quarter Results
NeoPharm Sets Conference Call and Webcast for Third Quarter Results
LAKE FOREST, Ill., Oct. 31 /PRNewswire-FirstCall/ -- NeoPharm, Inc. announced
today that its regular quarterly update and conference call to discuss results
for the third quarter ended September 30, 2003 will be held on Friday, November
14, 2003 at... More...>> |
|
|
|